tirzepatide is FDA- and EMA-approved (Mounjaro/Zepbound)
In April 2026, the FDA approved semaglutide 7.2 mg (Wegovy HD) under an accelerated review process
Patients treated with semaglutide, whether as diabetes medicine or as a weight loss treatment often experience common side effects
The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight regain observed in studies after discontinuation of anti-obesity medications
A humid bathroom cabinet or a travel container without the label can create avoidable problems
For peptides like semaglutide, the primary temperature-dependent degradation pathways include deamidation, where asparagine and glutamine residues lose their amide groups, and peptide bond hydrolysis, where the backbone of the molecule literally breaks apart